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Abstract
© 2018 by the authors. Recombinant viruses are novel therapeutic agents that can be utilized
for treatment of various diseases, including cancers. Recombinant viruses can be engineered to
express foreign transgenes and have a broad tropism allowing gene expression in a wide range
of host cells. They can be selected or designed for specific therapeutic goals; for example,
recombinant viruses could be used to stimulate host immune response against tumor-specific
antigens  and  therefore  overcome  the  ability  of  the  tumor  to  evade  the  host's  immune
surveillance. Alternatively, recombinant viruses could express immunomodulatory genes which
stimulate an anti-cancer immune response. Oncolytic viruses can replicate specifically in tumor
cells  and induce toxic  effects  leading to  cell  lysis  and apoptosis.  However,  each of  these
approaches face certain difficulties that must be resolved to achieve maximum therapeutic
efficacy. In this review we discuss actively developing approaches for cancer therapy based on
recombinant viruses, problems that need to be overcome, and possible prospects for further
development of recombinant virus based therapy.
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